BioSpectrum
the business of Bio & Health Sciences
ASIA EDITION

Cagent Vascular Wins CE Mark for its next generation device for Vessel Dilatation

24 November 2017 | News

The Serranator® is one of a family of peripheral artery disease (PAD) technologies which incorporates proprietary Serration Technology to an angioplasty balloon



Developer of next generation technology for vessel dilatation in cardiovascular disease interventions, Cagent Vascular has announced the issuance of its CE Marking for the Serranator® PTA Serration Balloon Catheter.

The Serranator® is one of a family of peripheral artery disease (PAD) technologies which incorporates proprietary Serration Technology to an angioplasty balloon. It has four embedded metal strips on an angioplasty balloon designed to create multiple longitudinal lines of interrupted micro-serrations to aid arterial expansion. Material that is serrated is more responsive to directed energy. In angioplasty, the serrated lines are more responsive to the balloon's energy, thus achieving lumen expansion in a controlled and predictable way.

Dr. Peter Schneider, Chief Medical Officer and co-founder of the company said, "Angioplasty is simple and inexpensive but doesn't work very well. A distinct and unique advantage of the Serranator® is that it capitalizes on the simplicity and familiarity of angioplasty while introducing a new and more effective method of vessel expansion."

Carol Burns, CEO of the company said, "Achieving CE Marking is an important milestone as we build upon physician enthusiasm for our device and finalize plans for successful commercialization. In addition to the Serranator® Alto device for use in treating diseased SFA and popliteal arteries, we are developing the Serranator® Bass for the infrapopliteal arteries. Both devices are expected to be part of the commercial product offering in 2018. We believe both devices have the potential to be best-in-class devices."